Federal Circuit rejects challenge to GSK’s Avodart and Jalyn

28-02-2014

Federal Circuit rejects challenge to GSK’s Avodart and Jalyn

Photo: GSK's corporate headquarters in Brentford, London / Courtesy of GSK

The US Appeals Court for the Federal Circuit has affirmed a lower court decision that GlaxoSmithKline’s (GSK’s) patent covering Avodart and Jalyn is valid, rejecting claims put forward by a group of generic drug makers.


GSK, Mylan, Avodart, Jalyn, patent validity

LSIPR